Pharmacologic evaluation of ospemifene

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 6, 2010, Pages 773-779

  Mccall, Jamie L ^a   Degregorio, Michael W ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dyspareunia; Non hormonal estrogen receptor agonist antagonist; Ospemifene; Vulvovaginal atrophy

Indexed keywords

OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AREA UNDER THE CURVE; ARTHRALGIA; BREAST CANCER; BREAST TENDERNESS; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPAREUNIA; FORMICATION; GROWTH INHIBITION; HEART PALPITATION; HOT FLUSH; HUMAN; INSOMNIA; LEUKORRHEA; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANCHOLIA; MYALGIA; NERVOUSNESS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARESTHESIA; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINITIS; VERTIGO; WEAKNESS; ANALOGS AND DERIVATIVES; ATROPHY; DRUG EFFECTS; FEMALE; PATHOLOGY; VAGINA; VULVA;

ATROPHY; FEMALE; HUMANS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VAGINA; VULVA;

EID: 77952518682     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.487483     Document Type: Review

References (42)

1. Simon JA, Komi J. Vulvovaginal atrophy (VVA) negatively impacts sexual function, psychosocial well-being, and partner relationships [Poster/Abstract LB-10]. 18th Annual Meeting of The North American Menopause Society. 3-6 October 2007; Dallas, TX
2. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61(1):178-80
3. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009;12(2):91-105
4. Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26(5):503-15
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33
6. Santoro N, Komi J. High prevalence and impact of vaginal symptoms among postmenopausal women [Abstract/Poster P-51]. 19th Annual Conference of The North American Menopause Society: 24-27 September 2008; Orlando, FL
7. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006; (4):CD001500
8. Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996; 174 (1 ' Pt 1):85-92
9. Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U. S. Maturitas 1995;22(Suppl):S43-7
10. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16(2):145-54
11. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003;45(1):29-38
12. Williams RE, Levine KB, Kalilani L, et al. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas 2009;62(2):153-9
13. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291(1):47-53
14. Rutanen EM, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 2003;10(5):433-9
15. Voipio SK, Komi J, Kangas L, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43(3):207-14
16. Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18(3):152-8
17. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005;12(2):202-9
18. Michael H, Harkonen PL, Kangas L, et al. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol 2007;151(3):384-95
19. Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999;73(4):500-7
20. Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005;7 (6):R881-9
21. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77(4-5):271-9
22. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 2005;97(3):230-40
23. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141(2):809-20
24. Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295(2):431-7
25. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18(17):3172-86
26. DeGregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy) toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol 2000;56(6-7):469-75
27. Anttila M, inventor Hormos Medical Corporation (Turku, FI), assignee. Method for enhancing the bioavailability of ospemifene. US 0182143; 2005
28. Gennari L. Ospemifene hormos. Curr Opin Investig Drugs 2004;5(4):448-55
29. Taras TL, Wurz GT, Linares GR, DeGregorio MW. Clinical pharmacokinetics of toremifene. Clin Pharmacokinet 2000;39(5):327-34
30. Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 2003;10(5):440-7
31. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999;281(23):2189-97
32. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90(18):1371-88
33. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 2005;116(1):1-13
34. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24(4):314-18
35. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2009; 17 (3) [Epub ahead of print]
36. QuatRx. QuatRx annouces further positive phase 3 results for ophena (ospemifene tablets) in postmenopausal vaginal atrophy. 29 July 2009. Press Release. Available from: http://www.quatrx.com/news/07-29-09.htm [Cited 22 December 2009]
37. QuatRx. QuatRx announces positive results of second Pivotal Phase 3 Clinical Study for ophena (ospemifene tablets) in treatment of postmenopausal vaginal atrophy. 10 September 2009. Press Release. Available from: http://www.quatrx.com/news/09-10-09. htm [Cited 22 December 2009]
38. Portman D, Komi J. Long-term effects of ospemifene on the clinical signs of vaginal atrophy [Abstract/Poster P-42]. 20th Annual Meeting of The North American Menopause Society:
39. September - 3 October 2009; San Diego, CA
40. QuatRx. QuartRx announces positive results of second Pivotal Phase 3 Clinical Study for ophena (ospemifene tablets) in treatment of postmenopausal vaginal atrophy. 10 September 2009. Press Release. Available from: http://www.quatrx.com/news/09-10-09. htm [Cited 22 December 2009]
41. Labrie F, Martel C, Gauthier S, et al. Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues. Hormone molecular biology and clinical investigation 2009;1(3):139-46
42. Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat 2000;60(1):63-70